• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

低亲和力物质对去纤苷(Org 10172)在人血浆中的抗血栓活性无贡献。

Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.

作者信息

Zammit A, Dawes J

机构信息

Heart Research Institute, Sydney, Australia.

出版信息

Thromb Haemost. 1994 Jun;71(6):759-67.

PMID:7526481
Abstract

Orgaran is a LMW heparinoid composed of heparan sulphate (83% w/w) of which 4-5% has high affinity for antithrombin, dermatan sulphate (12% w/w) and chondroitin sulphate (5% w/w). To examine the contribution of the low-affinity fraction to Orgaran's antithrombotic activity we have quantitated the binding of plasma proteins to Orgaran and its component fractions in whole, hirudin-anticoagulated human plasma. Antithrombin, largely bound to the high-affinity fraction, and histidine-rich glycoprotein, interacting with low-affinity components, were the dominant proteins bound to Orgaran. Vitronectin, fibrinogen, fibronectin, heparin cofactor II, and apolipoprotein B were also detected in small amounts. The ratio of bound antithrombin, histidine-rich glycoprotein and vitronectin to GAG was negatively correlated with the Orgaran concentration in plasma, implying that the efficacy of Orgaran may not be linearly related to dose. Binding of antithrombin to the high-affinity fraction was not decreased by other plasma proteins or affected by addition of low-affinity material. Moreover, the antithrombin and anti-factor Xa activities of the high-affinity material were unaltered by low-affinity GAGs. On the basis of our results we conclude that the low-affinity material does not contribute to the antithrombotic activity of Orgaran by binding non-anticoagulant plasma proteins and releasing the high-affinity chains to interact with antithrombin and its target proteinases.

摘要

奥加诺(Orgaran)是一种低分子量类肝素,由硫酸乙酰肝素(83% w/w)、硫酸皮肤素(12% w/w)和硫酸软骨素(5% w/w)组成,其中4 - 5%的硫酸乙酰肝素对抗凝血酶具有高亲和力。为了研究低亲和力部分对奥加诺抗血栓活性的贡献,我们在水蛭素抗凝的人全血浆中定量了血浆蛋白与奥加诺及其组成部分的结合情况。抗凝血酶主要与高亲和力部分结合,富含组氨酸糖蛋白与低亲和力成分相互作用,它们是与奥加诺结合的主要蛋白质。此外,还检测到少量的玻连蛋白、纤维蛋白原、纤连蛋白、肝素辅因子II和载脂蛋白B。结合的抗凝血酶、富含组氨酸糖蛋白和玻连蛋白与糖胺聚糖的比例与血浆中奥加诺的浓度呈负相关,这意味着奥加诺的疗效可能与剂量并非线性相关。其他血浆蛋白不会降低抗凝血酶与高亲和力部分的结合,添加低亲和力物质也不会影响这种结合。此外,低亲和力糖胺聚糖不会改变高亲和力物质的抗凝血酶和抗Xa因子活性。基于我们的研究结果,我们得出结论:低亲和力物质不会通过结合非抗凝血浆蛋白并释放高亲和力链以与抗凝血酶及其靶蛋白酶相互作用来对奥加诺的抗血栓活性产生贡献。

相似文献

1
Low-affinity material does not contribute to the antithrombotic activity of Orgaran (Org 10172) in human plasma.低亲和力物质对去纤苷(Org 10172)在人血浆中的抗血栓活性无贡献。
Thromb Haemost. 1994 Jun;71(6):759-67.
2
Anticoagulant mechanisms of Orgaran (Org 10172) and its fraction with high affinity to antithrombin III (Org 10849).奥加诺(Org 10172)及其与抗凝血酶III高亲和力组分(Org 10849)的抗凝机制。
Haemostasis. 1992;22(2):66-72. doi: 10.1159/000216297.
3
Orgaran (Org 10172): its pharmacological profile in experimental models.奥曲肽(Org 10172):其在实验模型中的药理学特性。
Haemostasis. 1992;22(2):58-65. doi: 10.1159/000216296.
4
Effect of oversulphated chondroitin and dermatan sulphate upon thrombin and factor Xa inactivation by antithrombin III or heparin cofactor II.过度硫酸化软骨素和硫酸皮肤素对抗凝血酶III或肝素辅因子II灭活凝血酶和因子Xa的影响。
Biochem J. 1988 Sep 1;254(2):547-51. doi: 10.1042/bj2540547.
5
Mechanisms for the anticoagulant effect of heparin and related polysaccharides.肝素及相关多糖的抗凝作用机制。
Nouv Rev Fr Hematol (1978). 1988;30(3):155-60.
6
Heparan sulfate and dermatan sulfate inhibit the generation of thrombin activity in plasma by complementary pathways.硫酸乙酰肝素和硫酸皮肤素通过互补途径抑制血浆中凝血酶活性的产生。
Blood. 1984 Sep;64(3):742-7.
7
Pharmacokinetic considerations on Orgaran (Org 10172) therapy.关于奥加兰(Org 10172)治疗的药代动力学考量
Haemostasis. 1992;22(2):73-84. doi: 10.1159/000216298.
8
Danaparoid: an anti-thrombotic agent without major impact on triglyceride hydrolysis capacity in humans.达那肝素:一种对人体甘油三酯水解能力无重大影响的抗血栓形成药物。
J Intern Med. 1998 Aug;244(2):184. doi: 10.1046/j.1365-2796.1998.0371b.x.
9
Pentasaccharide and Orgaran arrest, whereas heparin delays thrombus formation in a rat arteriovenous shunt.五糖和奥曲肽可阻止血栓形成,而肝素可延缓大鼠动静脉分流术中血栓的形成。
Thromb Haemost. 1993 Jan 11;69(1):29-34.
10
New antithrombotic agents for the prevention and treatment of deep vein thrombosis.用于预防和治疗深静脉血栓形成的新型抗血栓药物。
Haemostasis. 1996 Oct;26 Suppl 4:368-78. doi: 10.1159/000217318.

引用本文的文献

1
Danaparoid. A review of its pharmacology and clinical use in the management of heparin-induced thrombocytopenia.达那肝素。其药理学及在肝素诱导的血小板减少症管理中的临床应用综述。
Drugs. 1997 Dec;54(6):903-24. doi: 10.2165/00003495-199754060-00008.
2
Novel antithrombotic drugs in development.正在研发的新型抗血栓药物。
Drugs. 1995 Jun;49(6):856-84. doi: 10.2165/00003495-199549060-00002.